Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF supplemented embryo culture medium for recurrent pregnancy loss
PACTR202105562059108Not yet recruiting
- Sponsor
- Adam International Hospital
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of sargramostim in recurrent miscarriage (RPL) (2 arms), sponsored by Adam International Hospital. Primary endpoint: Continued pregnancy. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
sargramostim
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on PACTR202105562059108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202105562059108.